0001609351-17-000080.txt : 20170726
0001609351-17-000080.hdr.sgml : 20170726
20170726161429
ACCESSION NUMBER: 0001609351-17-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170725
FILED AS OF DATE: 20170726
DATE AS OF CHANGE: 20170726
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: High Katherine A
CENTRAL INDEX KEY: 0001631248
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36819
FILM NUMBER: 17982986
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spark Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609351
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462654405
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 888-772-7560
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
wf-form4_150110005560658.xml
FORM 4
X0306
4
2017-07-25
0
0001609351
Spark Therapeutics, Inc.
ONCE
0001631248
High Katherine A
C/O SPARK THERAPEUTICS, INC.
3737 MARKET STREET, SUITE 1300
PHILADELPHIA
PA
19104
1
1
0
0
See Remarks
Common Stock
2017-07-25
4
M
0
10000
3.45
A
220000
D
Common Stock
2017-07-25
4
S
0
8500
72.25
D
211500
D
Common Stock
2017-07-25
4
S
0
1500
74.11
D
210000
D
Stock Option (right to buy)
3.45
2017-07-25
4
M
0
10000
0
D
2024-07-02
Common Stock
10000.0
98249
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.85, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter.
President and Chief Scientific Officer
/s/ Joseph W. La Barge, attorney-in-fact for Katherine A. High
2017-07-26